# Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

> **NCT04114136** · PHASE2 · RECRUITING · sponsor: **Dan Zandberg** · enrollment: 72 (estimated)

## Conditions studied

- Melanoma
- NSCLC
- Hepatocellular Carcinoma
- Urothelial Cancer
- Gastric Adenocarcinoma
- HNSCC
- Esophageal Adenocarcinoma
- Microsatellite Instability-High Solid Malignant Tumor

## Interventions

- **DRUG:** Nivolumab or Pembrolizumab (dependent upon approved indication)
- **DRUG:** Metformin
- **DRUG:** Rosiglitazone

## Key facts

- **NCT ID:** NCT04114136
- **Lead sponsor:** Dan Zandberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-14
- **Primary completion:** 2025-08-08
- **Final completion:** 2027-10-02
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04114136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04114136, "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04114136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*